HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth

HealthEquity (HQY) is expected to report earnings for the quarter ending April 2025 on June 3, 2025, with consensus estimates projecting EPS of $0.81, a 1.3% year-over-year increase, and revenues of $321.13 million, up 11.7%. Despite a slight downward revision in EPS estimates over the last 30 days, HealthEquity has a positive Earnings ESP of +0.35% and a Zacks Rank #2, suggesting a likely earnings beat; however, investors should consider broader market factors in addition to the earnings report.

Analysis

HealthEquity (HQY) is poised to release its financial results for the quarter ended April 2025 on June 3, 2025, with consensus forecasts anticipating earnings per share (EPS) of $0.81, a modest 1.3% year-over-year growth, alongside revenues of $321.13 million, marking an 11.7% increase from the corresponding period last year. Despite a slight 0.24% downward revision in the consensus EPS estimate over the past month, HealthEquity's current analytical profile suggests a strong likelihood of outperforming these expectations. The company exhibits a positive Zacks Earnings ESP (Expected Surprise Prediction) of +0.35%, signifying that the most recent analyst estimates are more bullish than the broader consensus, and it holds a Zacks Rank #2 (Buy). This combination historically correlates with an approximately 70% probability of an earnings beat. While HealthEquity surpassed EPS estimates in three of the last four quarters, it did report a -2.82% earnings miss in its most recent quarter (actual $0.69 versus $0.71 expected). The overall sentiment from provided signals is "strongly positive" (score 0.65), and the tone is characterized as "bullish," which aligns with the potential for a positive earnings surprise.

Key Decisions for Investors

• Investors should consider HealthEquity's combination of a +0.35% Earnings ESP and a Zacks Rank #2, which collectively indicate a high probability of an EPS beat that could positively impact the stock price post-announcement.
• Beyond the headline EPS figure, it is crucial to scrutinize the reported revenue growth against the expected 11.7% year-over-year increase and closely analyze management's commentary on business conditions and forward guidance, as these will be key determinants of sustained stock performance.
• While an earnings beat seems probable, investors should also weigh the modest 1.3% year-over-year EPS growth expectation and the -2.82% earnings miss in the prior quarter, ensuring a comprehensive assessment of the earnings quality and growth sustainability.